



[2+2] Cycloaddition of electron-poor acetylenes to (*E*)-3-dimethylamino-1-heteroaryl-prop-2-en-1-ones: synthesis of highly functionalized 1-heteroaryl-1,3-butadienes

Jure Bezenšek, Tanja Koleša, Uroš Grošelj, Jernej Wagger, Katarina Stare, Anton Meden, Jurij Svete, Branko Stanovnik*

Faculty of Chemistry and Chemical Technology, University of Ljubljana, Aškerčeva 5, PO Box 537, 1000 Ljubljana, Slovenia

ARTICLE INFO

Article history:

Received 4 March 2010

Revised 2 April 2010

Accepted 23 April 2010

Available online 28 April 2010

Keywords:

[2+2] Cycloaddition

(*E*)-3-Dimethylamino-1-heteroaryl-prop-2-en-1-ones

1-Heteroaryl-1,3-butadienes

ABSTRACT

Microwave-assisted [2+2] cycloaddition of (*E*)-3-dimethylamino-1-heteroaryl-prop-2-en-1-ones to dimethyl acylenedicarboxylates gives (*2E,3E*)-dimethyl-2-[(dimethylamino)methylene]-3-(substituted)succinates in 8–91% yield. In the case of a 4,5-dihydrothiazoline derivative, cycloaddition also took place at the endocyclic C=N double bond.

© 2010 Elsevier Ltd. All rights reserved.

1. Introduction

The [2+2] cycloaddition of an alkene to an alkyne represents an important strategy for the synthesis of cyclobutene derivatives. It can be achieved by photochemical methods, thermal reactions via biradical intermediates¹ and by the use of Lewis acid catalysts.^{2a–c} Recently, the formal [2+2] cycloaddition of strong electron-acceptors to electron-rich alkynes followed by retro-electrocyclization has been studied in detail.^{3a–c} On the other hand, the wide applicability of 3-(dimethylamino)propenoates and related enamines as versatile reagents in heterocyclic synthesis,^{4a–d} including natural products and their analogues, for example, the aplysinopsins,^{5a,b} meridianines,^{6a,b} dipodazines^{7a–c} and triprostatines,⁸ has been demonstrated. This encouraged us to study their reactions with electron-poor acetylenes. Recently, we reported regioselective microwave-assisted [2+2] cycloadditions of substituted 2-amino-3-(dimethylamino)propenoates with acylenedicarboxylates which gave highly functionalized 1-amino-4-(dimethylamino)buta-1,3-dienes⁹ and their transformations into highly substituted pyridines, pyrroles and pyrido[3,4-*c*]pyridazine derivatives.¹⁰ These cycloadditions have been extended to (5*Z*)-5-[(dimethylamino)methylene]-3-methyl-imidazolidine-2,5-diones, resulting in the formation of (1*E*,3*E*)-1-(acylamino)-4-(dimethyl-

amino)buta-1,3-dienes.¹¹ In this Letter, we report the preparation of highly functionalized 1-heteroarylbuta-1,3-dienes via [2+2] cycloaddition of dimethyl acylenedicarboxylate (DMAD) to (*E*)-3-dimethylamino-1-heteroaryl-prop-2-en-1-ones.


2. Results and discussion

When (*E*)-3-(dimethylamino)-1-heteroaryl-prop-2-en-1-ones **2a–f** and **12a** prepared from acetyl heterocycles **1a–f** and **12b** and *N,N*-dimethylformamide dimethylacetal (DMFDMA) or *tert*-butoxy bis(dimethylamino)methane (TBDMA) were reacted under microwave irradiation at elevated temperatures with DMAD (**3**), as an electron-poor acetylene, the corresponding dimethyl (*2E,3E*)-2-[(dimethylamino)methylene]-3-(substituted)succinates **4a–f** and **14** were isolated as the only isomers in 8–91% yield (Schemes 1 and 3).

The structures of the products were determined by spectroscopic methods (IR, ¹H and ¹³C NMR, MS) and by elemental analyses. Additionally, the structures of compounds **2f**, **4d** and **13a,b** were confirmed by X-ray diffraction analysis (Figs. 1, 2, 4 and 5).

Two pathways for this cycloaddition can be envisioned, concerted and stepwise. In the case of a concerted cycloaddition, the reaction should proceed as a [2_s+2_a] cycloaddition resulting in cyclobutene intermediate **9**, which would undergo a conrotatory retro-electrocyclization (ring-opening) to afford (*2E,3E*)-**10** and/or (*2Z,3Z*)-**11**. In the case of a two-step mechanism, the initially formed intermediate **5** can be transformed into **5'** by rotation

* Corresponding author. Tel.: +386 1 2419 100; fax: +386 1 2419 220.
E-mail address: branko.stanovnik@fkkt.uni-lj.si (B. Stanovnik).



Scheme 1. Microwave-assisted [2+2] cycloaddition.

around the single bond. Cyclization of **5** leads to trans-cyclobutene intermediate **9**, whereas cyclization of **5'** would give sterically unfavoured cis-cyclobutene intermediate **6**, which upon a conrotatory retro-electrocyclization would produce isomers (2*Z*,3*E*)-**7** and/or (2*E*,3*Z*)-**8** (Scheme 2).

The single crystal X-ray structure of product **4d** (Fig. 2) clearly demonstrates the (2*E*,3*E*) configuration at the C=C double bonds. On the other hand, the configurations at the C=C double bonds in products **4c** and **4f** were determined by NMR on the basis of long-range coupling constants, $^3J_{C-H}$, between the corresponding methine protons and the carbonyl carbon atoms, measured from the antiphase splitting of cross peaks in the HMBC spectrum. Generally, the magnitude of the coupling constants, $^3J_{C-H}$, for nuclei with a cis-configuration at the C=C double bond is smaller (2–6 Hz) than that of trans-oriented nuclei (8–12 Hz).¹² The magnitude of the coupling constants, $^3J_{C(1)-H(2')} = 4.5$ Hz and $^3J_{C(1)-H(2'')} = 4.8$ Hz, for compounds **4c** and **4f**, respectively, indicates a (2*E*)-configuration. Similarly, in the (3*E*)-configuration was established for both compounds **4c** and **4f** ($^3J_{C(3)-H(3')} = 6.9$ Hz) (Fig. 3). Finally, selected ¹H NMR data of cycloadducts **4a–f** and **14** correlate well, implying their uniform (2*E*,3*E*) configuration. This in turn indicates that the cycloaddition reactions could proceed either by a concerted mechanism or by a two-step mechanism in which rotation around the single bond is restricted due to the formation of sterically less favored cis-cyclobutene derivative **6**.

The cycloaddition of (*E*)-1-(4,5-dihydrothiazol-2-yl)-3-(dimethylamino)prop-2-en-1-one (**12a**), prepared from 1-(4,5-dihydrothiazol-2-yl)ethanone (**12b**) and DMFDMA, with DMAD (**3**), under microwave irradiation, afforded a mixture of the corresponding [2+2] cycloadduct **14** in 8% yield and (*E*)-dimethyl 6-[2-(dimethylamino)vinyl]-5-oxo-2,3,5,7a-tetrahydropyrrolo[2,1-*b*]thiazole-7,7a-dicarboxylate (**13a**) in 32% yield (Scheme 3).



The elemental analysis and HRMS spectrum for the minor product **14** gave a molecular formula of C₁₄H₁₈N₂O₅S, corresponding to 1:1 adduct. The ¹H NMR spectrum exhibited a singlet at 2.84 ppm

integrating for 6 protons (NMe₂ group), two triplets at 3.32 and 4.55 ppm, each integrating for two protons, (*J* = 8.7 Hz, –CH₂CH₂– group), two singlets at 3.64 and 3.81 ppm, each integrating for three protons (two ester Me groups) and two singlets, each integrating for one proton at 7.70 and 7.89 ppm for C2'-H and C3'-H. On the basis of these data and their close ¹H NMR correlation with analogous cycloadducts **4a–f** (see Table 1), one can conclude that the cycloaddition of DMAD took place at the exocyclic C=C double bond of **12a**, thus forming product **14**.

The elemental analysis and HRMS for the major product **13a** gave a molecular formula of C₁₄H₁₈N₂O₅S, also corresponding to 1:1 adduct. The ¹H NMR spectrum exhibited a singlet at 3.00 ppm (6H, NMe₂ group), two multiplets at ~3.41 ppm (3H) and ~4.29 ppm (1H) for the –CH₂CH₂– group, two singlets at 3.72 (3H) and 3.80 ppm (3H) for the two ester Me groups and two doublets at 5.98 (1H) and 8.49 ppm (1H) (*J* = 13.2 Hz) for the –CH=CH– (trans) structural element. On the basis of these data, we assumed that the cycloaddition of DMAD to **12a** must have taken place at the C=N double bond of the thiazolidine ring. The single crystal X-ray structure confirmed the structure of compound **13a** (Fig. 4).

Similarly, the cycloaddition of DMAD to 1-(4,5-dihydrothiazol-2-yl)ethanone (**12b**) produced a compound with the molecular formula C₁₁H₁₃NO₅S, corresponding again to a 1:1 cycloadduct. The ¹H NMR spectrum showed a singlet at 2.19 ppm (3H) for the Me group, three multiplets at ~3.36 ppm (1H), ~3.53 ppm (2H) and ~4.30 ppm (1H) for the –CH₂CH₂– structural element and two singlets at 3.77 ppm (3H) and 3.88 ppm (3H) for the two ester Me groups. The structure of this cycloadduct is similar to the structure of compound **13a** and was confirmed by single crystal X-ray analysis (Fig. 5).

We rationalize the formation of compound **13b** by initial [2+2] cycloaddition of DMAD to the endocyclic C=N double bond of **12b** to form the intermediate cycloadduct **15**, followed by a series of 1,3-sigmatropic shifts **15**→**16**→**17**→**18** to finally arrive at **13b** (Scheme 4).



3. Experimental

3.1. General procedure for the synthesis of (*E*)-3-(dimethylamino)-1-substituted-prop-2-en-1-ones **2a–f** and **12a**¹³

To compound **1a–f**, **12b** (1 equiv) was added DMFDMA or TBDMAM (1.2 equiv) and the resulting mixture was stirred in a closed vessel under microwave irradiation (300 W) at an automatically controlled constant temperature (CEM Corporation discover microwave unit). After cooling to room temperature, the volatile compo-

nents were evaporated in vacuo and the residue was purified by column chromatography (products **2a,e**, **12a**) or crystallization (products **2b,c,d,f**).

3.2. General procedure for the synthesis of (*2E,3E*)-dimethyl 2-[(dimethylamino)methylene]-3-(2-substituted)succinates **4a–f**

To a solution of (*E*)-3-(dimethylamino)-1-substituted-prop-2-en-1-one **2a–f** (1 equiv) in MeCN (1–3 mL) was added DMAD (**3**) (2.0–2.5 equiv) and the mixture was stirred in a closed vessel




Figure 1. ORTEP view of compound 2f.




Figure 4. ORTEP view of compound 13a.




Figure 2. ORTEP view of compound 4d.




Figure 5. ORTEP view of compound 13b.





Figure 3. Determination of the configuration by HMBC spectroscopy.

Table 1
Selected ^1H NMR data of cycloadducts 4a–f and 14

Product	δ NMe ₂ (ppm)	δ COOMe (ppm)	δ H ^{3'} (ppm)	δ H ^{2'} (ppm)
4a	2.89	3.62	7.53	7.77
		3.83		
4b	2.89	3.62	7.47	7.72
		3.82		
4c	2.89	3.60	7.52	7.67
		3.83		
4d	2.89	3.60	7.48	7.56
		3.83		
4e	2.90	3.82	7.53	7.56
		3.90		
4f	2.90	3.65	7.39	7.55
		3.81		
14	2.84	3.64	7.70	7.89
		3.81		

under microwave irradiation (300 W) at automatically controlled elevated constant temperature (CEM Corporation discover microwave unit) or at room temperature. After cooling to room temperature, volatile compounds were evaporated in vacuo and the

residue was purified by column chromatography (products 4a,b,c,e,f) or crystallization (product 4d).

Scheme 4. The proposed mechanism for the formation of **13b**.

3.3. (*E*)-Dimethyl 6-[2-(dimethylamino)vinyl]-5-oxo-2,3,5,7a-tetrahydropyrrolo[2,1-*b*]thiazole-7,7a-dicarboxylate (**13a**) and (*2E,3E*)-dimethyl 2-[2-(4,5-dihydrothiazol-2-yl)-2-oxoethylidene]-3-[(dimethylamino)methylene]succinate (**14**)

Prepared from (*E*)-1-(4,5-dihydrothiazol-2-yl)-3-(dimethylamino)prop-2-en-1-one (**12a**) (276 mg, 1.5 mmol) and DMAD (**3**) (366 μ L, 3.0 mmol) in MeCN (1.5 mL), 60 °C, 10 min. The two products were separated by column chromatography (EtOAc/petroleum ether = 1:2). Fractions containing the products were combined and evaporated in vacuo.

3.4. Major product **13a**

Elutes first, recrystallized from EtOAc/petroleum ether. Yield: 156 mg (32%); yellow solid; mp 103–115 °C. ^1H NMR (CDCl_3 , 300 MHz): δ 3.00 (6H, s, NMe_2); 3.31–3.53 (3H, m, 3H of thiazolidine); 3.72 (3H, s, COOMe); 3.80 (3H, s, COOMe); 4.29–4.36 (1H, m, 1H of thiazolidine); 5.98 (1H, d, $J = 13.2$ Hz, CH); 8.49 (1H, d, $J = 13.2$ Hz, CH). ^{13}C NMR (CDCl_3 , 75.5 MHz): δ 36.0, 43.9, 51.4, 53.5, 79.0, 90.1, 120.4, 140.4, 150.9, 164.4, 169.6, 172.3. ($\text{C}_{14}\text{H}_{18}\text{N}_2\text{O}_5\text{S}$ requires: C, 51.52; H, 5.56; N, 8.58; found C, 51.30; H, 5.56; N, 8.42); EI-HRMS: $m/z = 327.1012$ (MH^+); $\text{C}_{14}\text{H}_{19}\text{N}_2\text{O}_5\text{S}$ requires: $m/z = 327.1015$ (MH^+); ν_{max} (KBr) 2948, 1755, 1735, 1697, 1611, 1565, 1431, 1406, 1341, 1251, 1191, 1162, 1109, 1040, 1011, 974, 861 cm^{-1} .

3.5. Minor product **14**

Elutes second. Yield: 38 mg (8%); red oil. ^1H NMR (CDCl_3 , 300 MHz): δ 2.84 (6H, s, NMe_2); 3.32 (2H, t, $J = 8.7$ Hz, CH_2 of thiazolidine); 3.64 (3H, s, COOMe); 3.81 (3H, s, COOMe); 4.55 (2H, t, $J = 8.7$ Hz, CH_2 of thiazolidine); 7.70 (1H, s, C(3')-H); 7.89 (1H, s, C(2')-H). ^{13}C NMR (CDCl_3 , 75.5 MHz): δ 32.9, 43.9, 51.6, 53.1, 66.4, 93.3, 120.7, 142.4, 155.5, 168.7, 169.1, 172.2, 181.0. EI-HRMS: $m/z = 327.1006$ (MH^+); $\text{C}_{14}\text{H}_{19}\text{N}_2\text{O}_5\text{S}$ requires: $m/z = 327.1015$ (MH^+); ν_{max} (KBr) 2949, 1723, 1692, 1604, 1538, 1433, 1400, 1328, 1255, 1217, 1135, 1089, 1046, 997, 942, 923 cm^{-1} .

3.6. Dimethyl 6-methyl-5-oxo-2,3,5,7a-tetrahydropyrrolo[2,1-*b*]thiazole-7,7a-dicarboxylate (**13b**)

Prepared from 1-(4,5-dihydrothiazol-2-yl)ethanone (**12b**) (440 mg, 3.4 mmol) and DMAD (**3**) (830 μ L, 6.8 mmol) in MeCN (3 mL), 60 °C, 15 min, column chromatography (EtOAc/petroleum ether = 1:3), recrystallized from EtOAc/petroleum ether. Yield: 171 mg (19%); white solid; mp 106–109 °C. ^1H NMR (CDCl_3 , 300 MHz): δ 2.19 (3H, s, CH_3); 3.31–3.42 (1H, m, 1H of thiazolidine

CH_2); 3.48–3.57 (2H, m, CH_2 of thiazolidine); 3.77 (3H, s, COOMe); 3.88 (3H, s, COOMe); 4.29–4.40 (1H, m, 1H of thiazolidine CH_2). ^{13}C NMR (CDCl_3 , 75.5 MHz): δ 11.0, 36.9, 44.6, 52.5, 53.8, 78.3, 141.5, 143.0, 162.9, 168.5, 172.6. ($\text{C}_{11}\text{H}_{13}\text{NO}_5\text{S}$ requires: C, 48.70; H, 4.83; N, 5.16; found C, 48.75; H, 4.66; N, 5.07); EI-HRMS: $m/z = 272.0588$ (MH^+); $\text{C}_{11}\text{H}_{14}\text{NO}_5\text{S}$ requires: $m/z = 272.0593$ (MH^+); ν_{max} (KBr) 3008, 2959, 1734, 1706, 1464, 1438, 1347, 1326, 1278, 1217, 1161, 1071, 990, 955, 925 cm^{-1} .

3.7. X-ray structure analysis for compounds **2f**, **4d**, **13a** and **13b**

Single crystal X-ray diffraction data of compounds **2f**, **4d**, **13a** and **13b** were collected at room temperature on a Nonius Kappa CCD diffractometer using the Nonius Collect Software.¹⁴ DENZO and SCALEPACK¹⁵ were used for indexing and scaling of the data and the structures were solved by means of SIR97.¹⁶ Refinement was performed using the XTAL3.4¹⁷ program package and the crystallographic plots were prepared by ORTEP III.¹⁸ Crystal structures were refined on F values using the full-matrix least-squares procedure. The non-hydrogen atoms were refined anisotropically in all cases, while the positions of the hydrogen atoms were geometrically calculated and their positional and isotropic atomic displacement parameters were not refined. Absorption correction was not necessary. Regina¹⁹ weighting scheme was used in all cases.

Acknowledgements

Financial support from the Slovenian Research Agency through grants P0-0502-0103, P1-0179 and J1-6689-0103-04 is gratefully acknowledged. We also thank the Krka d.d. (Novo mesto, Slovenia) and Lek d.d., a Sandoz Company (Ljubljana, Slovenia) for financial support.

Supplementary data

Crystallographic data (excluding structure factors) for the structures in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication numbers CCDC 768092 (**2f**), 768093 (**4d**), 768094 (**13a**) and 768095 (**13b**). Copies of these data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge, CB2 1EZ, UK [fax: +44(0)-1223-336033 or e-mail: deposit@ccdc.cam.ac.uk]. Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.tetlet.2010.04.106.

References and notes

1. Trost, B. M., Fleming, I., Paquette, L. A., Eds. *Comprehensive Organic Synthesis*; Oxford: Pergamon, 1991; Vol. 5., Chapters 2.1–2.6.

2. (a) Cockburn, N.; Karimi, E.; Tam, W. *J. Org. Chem.* **2009**, *74*, 5762–5765. and reference cited therein; (b) Fan, B.-M.; Li, X.-J.; Peng, F.-Z.; Zhang, H.-B.; Chan, A. S. C.; Shao, Z. H. *Org. Lett.* **2010**, *12*, 304–306; (c) Shibata, T.; Tsuchikama, K. *Org. Biomol. Chem.* **2008**, *6*, 1317–1323.
3. (a) Kivala, M.; Boudon, C.; Gisselbrecht, J.-P.; Seiler, P.; Gross, M.; Diederich, F. *Chem. Commun.* **2007**, 4731–4733; (b) Jarowski, P. D.; Wu, Y. L.; Boudon, C.; Gisselbrecht, J.-P.; Gross, M.; Schweizer, W. B.; Diederich, F. *Org. Biomol. Chem.* **2009**, *7*, 1312–1322; (c) Wu, Y. L.; Jarowski, P. D.; Schweizer, W. B.; Diederich, F. *Chem. Eur. J.* **2010**, *16*, 202–211.
4. (a) Stanovnik, B. *J. Heterocycl. Chem.* **1999**, *36*, 1581–1593; (b) Stanovnik, B.; Svete, J. *Synlett* **2000**, 1077–1091; (c) Stanovnik, B.; Svete, J. In Attanasi, O. A., Spinelli, D., Eds.; *Targets in Heterocyclic Systems. Synthesis, Reactions and Properties*; Italian Society of Chemistry: Rome, 2000; Vol. 3, pp 105–137; (d) Stanovnik, B.; Svete, J. *Chem. Rev.* **2004**, *104*, 2433–2480.
5. (a) Selič, L.; Jakše, R.; Lampič, K.; Golič, L.; Golič Grdadolnik, S.; Stanovnik, B. *Helv. Chim. Acta* **2000**, *83*, 2802–2811; (b) Selič, L.; Stanovnik, B. *Tetrahedron* **2001**, *57*, 3159–3164.
6. (a) Jakše, R.; Svete, J.; Stanovnik, B. *Tetrahedron* **2004**, *60*, 4601–4608; (b) Časar, Z.; Bevk, D.; Svete, J.; Stanovnik, B. *Tetrahedron* **2005**, *61*, 7508–7519.
7. (a) Wagger, J.; Bevk, D.; Meden, A.; Svete, J.; Stanovnik, B. *Helv. Chim. Acta* **2006**, *89*, 240–248; (b) Wagger, J.; Golič Grdadolnik, S.; Grošelj, U.; Meden, A.; Stanovnik, B.; Svete, J. *Tetrahedron: Asymmetry* **2007**, *18*, 464–475; (c) Wagger, J.; Grošelj, U.; Meden, A.; Svete, J.; Stanovnik, B. *Tetrahedron* **2008**, *64*, 2801–2815.
8. Wagger, J.; Svete, J.; Stanovnik, B. *Synthesis* **2008**, 1436–1442.
9. Uršič, U.; Grošelj, U.; Meden, A.; Svete, J.; Stanovnik, B. *Tetrahedron Lett.* **2008**, *49*, 3775–3778.
10. Uršič, U.; Svete, J.; Stanovnik, B. *Tetrahedron* **2008**, *64*, 9937–9946.
11. Uršič, U.; Grošelj, U.; Meden, A.; Svete, J.; Stanovnik, B. *Helv. Chim. Acta* **2009**, *92*, 481–490.
12. (a) Bax, A.; Freeman, R. *J. Am. Chem. Soc.* **1982**, *104*, 1099–1100; (b) Titman, J. J.; Foote, J.; Jarvis, J.; Keeler, J.; Neuhaus, D. *J. Chem. Soc., Chem. Commun.* **1991**, 419–421; (c) Ando, T.; Koseki, N.; Toia, R. F.; Casida, J. E. *Magn. Reson. Chem.* **1993**, *31*, 90–93; (d) Fischer, P.; Schweizer, E.; Langner, J.; Schmidt, U. *Magn. Reson. Chem.* **1994**, *32*, 567–568; (e) Willker, W.; Leibfritz, D. *Magn. Reson. Chem.* **1995**, *33*, 632–638; (f) Golič Grdadolnik, S.; Stanovnik, B. *Magn. Reson. Chem.* **1997**, *35*, 482–486; (g) Ósz, E.; Szilágyi, L.; Marton, J. *J. Mol. Struct.* **1998**, *442*, 267–274; (h) Furihata, K.; Seto, H. *Tetrahedron Lett.* **1999**, *40*, 6271–6275; (i) Seki, H.; Tokunaga, T.; Utsumi, H.; Yamaguchi, K. *Tetrahedron* **2000**, *56*, 2935–2939; (j) Tokunaga, T.; Seki, H.; Yasuie, S.; Ikoma, M.; Kurita, J.; Yamaguchi, K. *Tetrahedron Lett.* **2000**, *41*, 1031–1034; (k) Ding, K. *Magn. Reson. Chem.* **2000**, *38*, 321–323.
13. Pleier, A.-K.; Glas, H.; Grosche, M.; Sirsch, P.; Thiel, W. R. *Synthesis* **2001**, 55–62.
14. Collect Software, Nonius, BV, Delft, The Netherlands, 1998.
15. Otwinowski, Z.; Minor, W. *Methods Enzymol.* **1997**, *276*, 307–326.
16. Altomare, A.; Burla, M. C.; Camalli, M.; Casciarano, G. L.; Giacovazzo, C.; Guagliardi, A.; Moliterni, A. G. G.; Polidori, G.; Spagna, R. *J. Appl. Crystallogr.* **1999**, *32*, 115–119.
17. Hall, S. R.; King, G. S. D.; Stewart, J. M. *The Xtal3.4 User's Manual*, University of Western Australia, Lamb, Perth, 1995.
18. Burnett, M. N.; Johnson, C. K. In ORTEP-III: Oak Ridge Thermal Ellipsoid Plot Program for Crystal Structure Illustrations, Oak Ridge National Laboratory Report ORNL-6895, 1996.
19. Wang, H.; Robertson, B. E. In *Structure and Statistics in Crystallography*; Wilson, A. J. C., Ed.; Adenine Press: New York, 1985.